Thomas H Aasen Net Worth

The estimated Net Worth of Thomas H Aasen is at least 3.93 百万$ dollars as of 12 December 2013. Thomas Aasen owns over 12,000 units of Cerecor Inc stock worth over 115,290$ and over the last 20 years Thomas sold CERC stock worth over 3,811,900$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Thomas Aasen CERC stock SEC Form 4 insiders trading

Thomas has made over 11 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Thomas sold 15,000 units of CERC stock worth 337,200$ on 4 April 2014.

The largest trade Thomas's ever made was selling 60,000 units of Cerecor Inc stock on 13 August 2013 worth over 1,209,000$. On average, Thomas trades about 7,671 units every 16 days since 2005. As of 12 December 2013 Thomas still owns at least 39,348 units of Cerecor Inc stock.

You can see the complete history of Thomas Aasen stock trades at the bottom of the page.

What's Thomas Aasen's mailing address?

Thomas's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO, CA, 92121.

Insiders trading at Cerecor Inc

Over the last 9 years, insiders at Cerecor Inc have traded over 0$ worth of Cerecor Inc stock and bought 18,463,844 units worth 43,946,959$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of 601,142$. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth 138,000$.

What does Cerecor Inc do?

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

Complete history of Thomas Aasen stock trades at Acadia Pharmaceuticals Inc、Cerecor Inc

Cerecor Inc executives and stock owners

Cerecor Inc executives and other stock owners filed with the SEC include:

• Joseph Miller,
  Director
• Jamie Harrell,
  Chief Commercial Officer
• Phil Gutry,
  Independent Director
• Magnus Persson,
  Independent Director
• Gilla Kaplan,
  Independent Director
• Steven Boyd,
  Independent Director
• Suzanne Bruhn,
  Director
• Jeff Wilkins,
  Chief Development Officer
• Garry Neil,
  Chief Scientific Officer
• Christopher Sullivan,
  Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• Michael Cola,
  Chief Executive Officer, Director
• Sol Barer,
  Chairman of the Board
• Thomas H Aasen,
  Director
• Mariam E Morris,
  Chief Financial Officer
• Ronald Marcus,
  Chief Medical Officer
• John Joseph Kaiser,
  Chief Business Officer
• Eugene A Bauer,
  Director
• Robert Jr. Moscato,
  Director
• Peter Greenleaf,
  Director
• Keith Schmidt,
  Director
• Pericles Calias,
  Chief Scientific Officer
• Matthew V Phillips,
  Chief Commercial Officer
• Randal Jones,
  Director
• Patrick J Crutcher,
  VP, Business Development
• Robert Jr.Lrs International...,
  
• Randal Fremantle, Llc Jones,
  
• Capital, Llc Boyd Steven Ar...,
  
• Simon Pedder,
  Executive Chairman of the Bd
• Uli Hacksell,
  Director
• Tree Partners Iv, L.P.Atp I...,
  
• David M Mott,
  10% owner
• Behshad Sheldon,
  Director
• Anthony A. Jr. Florence,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Peter W. Sonsini,
  10% owner
• Harry R Weller,
  10% owner
• Blake M Paterson,
  CEO and President
• Forest Baskett,
  10% owner
• Ravi Viswanathan,
  10% owner
• M James Barrett,
  10% owner
• Scott D Sandell,
  10% owner
• Enterprise Associates 14, L...,
  
• Bioventures V, L.P.Mpm Asse...,
  
• Peter J Barris,
  10% owner
• Patrick J Kerins,
  10% owner
• Isaac Blech,
  Director
• James Archie Jr Harrell,
  Chief Commercial Officer
• Schond L. Greenway,
  CFO